Transforming Pharma's Commercial Capabilities to Drive Maximum Value
Large pharmaceutical companies need to accelerate their changing competitive strategies, commercial capabilities, and organizational models to respond adequately to new market conditions. To maximize the value of products, consulting firm Booz Allen proposes aligning commercial operations along three distinct businesses, which cut across specialty and primary care segmentation and which are differentiated based on competitive strategies.
You may also be interested in...
The pending purchase of Wyeth will accelerate Pfizer's transformation from a mass marketer of superstar drugs into a diversified supplier of targeted therapies, consumer health, and other health care products. It is a major but incomplete step in the search for new growth drivers as Pfizer's cholesterol drug Lipitor--worth a quarter of the Big Pharma's 2008 revenues--loses exclusivity. The company has also restructured existing operations into six business units, the most intriguing of which is the Established Products Business Unit. That division has pulled together Pfizer's off-patent and branded older products into a $10 billion business, albeit one with declining sales. Its leader, David Simmons has the job of reversing the decline and creating a growth story.
Gilead ups its investment in its TIGIT partner, as the firms pivot to a less crowded market opportunity in upper GI cancers.
While an EU-level project is underway to address delays to drug trials that are conducted in combination with IVD performance studies, Denmark has streamlined its processes to address the issue at the national level.